Details for Patent: 9,145,389

« Back to Dashboard

Which drugs does patent 9,145,389 protect, and when does it expire?

Patent 9,145,389 protects DEXILANT SOLUTAB and DEXILANT and is included in two NDAs. There have been two Paragraph IV challenges on Dexilant.

This patent has forty-four patent family members in twenty-five countries.

Summary for Patent: 9,145,389

Title:	Benzimidazole compound crystal
Abstract:	A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-- 1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.
Inventor(s):	Fujishima; Akira (Hyogo, JP), Aoki; Isao (Hyogo, JP)
Assignee:	Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:	14/508,651
Patent Claim Types: see list of patent claims	Compound; Formulation; Composition;

Glossary

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance
Takeda Pharms Usa	DEXILANT SOLUTAB	dexlansoprazole	TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL	208056-001	Jan 26, 2016		DISCN	Yes	No	► Subscribe	► Subscribe	Y	Y
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-001	Jan 30, 2009		RX	Yes	No	► Subscribe	► Subscribe	Y	Y
Takeda Pharms Usa	DEXILANT	dexlansoprazole	CAPSULE, DELAYED RELEASE;ORAL	022287-002	Jan 30, 2009	AB	RX	Yes	Yes	► Subscribe	► Subscribe	Y	Y

This preview shows a limited data set Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 9,145,389

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	11-171509	Jun 17, 1999

Non-Orange Book Patents for Patent: 9,145,389

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No.	Title	Estimated Patent Expiration
7,569,697	Benzimidazole compound crystal	► Subscribe
6,462,058	Benzimidazole compound crystal	► Subscribe
8,552,198	Benzimidazole compound crystal	► Subscribe
8,884,019	Benzimidazole compound crystal	► Subscribe
6,939,971	Benzimidazole compound crystal	► Subscribe
7,339,064	Benzimidazole compound crystal	► Subscribe
7,737,282	Benzimidazole compound crystal	► Subscribe
6,664,276	Benzimidazole compound crystal	► Subscribe
8,030,333	Benzimidazole compound crystal	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,145,389

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1977751	► Subscribe
European Patent Office	1129088	► Subscribe	PA2014014	Lithuania	► Subscribe
European Patent Office	1129088	► Subscribe	PA2014014,C1129088	Lithuania	► Subscribe
European Patent Office	1129088	► Subscribe	2014/008	Ireland	► Subscribe
European Patent Office	1129088	► Subscribe	C01129088/01	Switzerland	► Subscribe
European Patent Office	1129088	► Subscribe	1490004-7	Sweden	► Subscribe
European Patent Office	1129088	► Subscribe	122014000036	Germany	► Subscribe
Mexico	PA01012642	► Subscribe
South Korea	100514204	► Subscribe
South Korea	20030068592	► Subscribe

This preview shows a limited data set Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

DrugPatentWatch Database Preview

Details for Patent: 9,145,389

« Back to Dashboard

Summary for Patent: 9,145,389

Glossary

Foreign Priority and PCT Information for Patent: 9,145,389

Non-Orange Book Patents for Patent: 9,145,389

International Patent Family for Patent: 9,145,389

For more information try a trial or see the database preview and plans and pricing

Get our Free Drug Patent Bulletin